SBFM
Sunshine Biopharma, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$1.14
+2.70%Year over year
Reported trailing growth
- Revenue
- -2.7%
- EBITDA
- +15.1%
- EBIT
- +4.3%
- EPS
- +87.9%
- Free cash flow
- +51.4%
- Operating cash flow
- +31.1%
Forward estimates
Based on analyst estimates
- Revenue
- -45.1%
- EBITDA
- +91.8%
- EPS
- +95.5%
Three-year CAGR
- Revenue
- +102.9%
- EBITDA
- -9.4%
- EBIT
- +22.9%
- Net income
- -16.4%
- EPS
- +80.3%
- Free cash flow
- +62.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026